Alpha's PR in English: (Translation provided by GOOGLE)
Alfasigma agrees with Innovation Pharmaceuticals for
develop and market Brilacidin in the treatment of
Ulcerative Proctitis and Ulcerative Proctosigmoiditis
• Innovation Pharmaceuticals & Alfasigma announced an agreement for
Brilacidin, in the treatment of Ulcerative Proctitis and Ulcerative Proctosigmoiditis
• For Alfasigma it is the second agreement in a few weeks that strengthens
pipeline and portfolio in the Gastrointestinal field
• The agreement starts from a base of 24 million dollars
Bologna, July 23, 2019 - Alfasigma Spa and Innovation Pharmaceuticals (OTCQB:
IPIX), a biopharmaceutical company based in the United States, have entered into a licensing agreement
for which Alfasigma will develop and market worldwide Brilacidin for use
local, for the treatment of Ulcerative Proctitis and Ulcerative Proctosigmoiditis (PU / PSU). There
Proctitis is an inflammatory disease of the rectum, which when extended also to
sigma is called Proctosigmoidite.
PU and PSU are therefore attributable to chronic intestinal inflammatory diseases (MICI,
also known as IBD - Inflammatory Bowel Disease: together they represent one
chronic and autoimmune condition difficult to treat affecting about 10 million people
all over the world, including 200,000 people in Italy.
Brilacidin will be developed as a new non-corticosteroid, non-biological treatment,
administered by different formulations, Alfasigma will initially develop
topical formulations such as enema, foams and / or gel for PU / PSU.
A few weeks after the announcement for the commercial re-introduction of Zelnorm
in the States - used for the treatment of irritable bowel syndrome
constipation - this is a further step in strengthening the pipeline in the Gastro-intestinal area.
"Alfasigma is developing, at a global level, a specific focus in the Gastrointestinal field",
stated Pier Vincenzo Colli, CEO of Alfasigma. "We are excited to add to the
our portfolio, this partnership with Innovation Pharmaceuticals. The results of the study
clinical on Phase 2 Brilacidin in PU / PSU seem promising and enhance properties
unique of the drug. To advance Brilacidin, we plan to allocate an important one
investment, both in terms of internal resources and expertise for formulations and protection
of intellectual property. "
We are proud to be able to work to offer patients a new and effective option
safe treatment in the management of PU / PSU ", continues Colli" We will also closely follow i
next developments of Innovation Pharmaceuticals in the development of oral Brilacidin, why
we are also interested in new treatments for mici. This agreement, along with that
a few weeks ago on Zelnorm, represents a further enhancement of ours
global pipeline ".
The agreement also includes a right of first refusal for Brilacidin in the treatment of forms
more extensive inflammatory bowel disease (IBD), such as ulcerative colitis and the
Crohn's disease and a first negotiation right for Brilacidin in other gastrointestinal indications. In addition to an initial outlay, the agreement provides for a series of additional payments
based on certain milestones, for a total of over $ 24 million and royalties of 6% on
net sales in the marketing of Brilacidin for PU / PSU.
Information on Alfasigma.
Alfasigma is one of the leading Italian pharmaceutical companies: present in over 90 countries,
has a workforce of around 3,000 people, Research and Development laboratories, and 5 factories
of production.
In Italy Alfasigma is a leader in the market for prescription products where, in addition to the strong focus
on Gastro-Intestinal, it is present in many primary care therapeutic areas. Produces and
it also markets self-medication products, nutraceuticals and food supplements.
For more information, visit www.alfasigma.com or send an e-mail to
info@alfasigma.com.
